Wei Shun-Guang, Yu Yang, Felder Robert B
Department of Internal Medicine, University of Iowa Carver College of Medicine , Iowa City, Iowa.
Veterans Affairs Medical Center , Iowa City, Iowa.
Am J Physiol Regul Integr Comp Physiol. 2018 Mar 1;314(3):R447-R458. doi: 10.1152/ajpregu.00211.2017. Epub 2017 Nov 22.
We previously reported that microinjection of the proinflammatory cytokine interleukin-1β (IL-1β) into the subfornical organ (SFO) elicits a pressor response accompanied by increases in inflammation and renin-angiotensin system (RAS) activity in the SFO and hypothalamic paraventricular nucleus (PVN). The present study sought to determine whether blood-borne IL-1β induces similar neurochemical changes in the SFO and PVN and, if so, whether increased inflammation and RAS activity at the SFO level orchestrate the sympathoexcitatory response to circulating IL-1β. In urethane-anesthetized male Sprague-Dawley rats, intravenous injection of IL-1β (500 ng) increased blood pressure, heart rate, renal sympathetic nerve activity, and mRNA for angiotensin-converting enzyme, angiotensin II type 1a receptor, cyclooxygenase-2, tumor necrosis factor-α, and IL-1β, as well as the tumor necrosis factor-α p55 receptor and the IL-1 receptor, in the SFO and PVN. Pretreatment with SFO microinjections of the angiotensin II type 1a receptor blocker losartan (1 µg), the angiotensin-converting enzyme inhibitor captopril (1 µg), or the cyclooxygenase-2 inhibitor NS-398 (2 µg) attenuated expression of these excitatory mediators in the SFO and downstream in the PVN and the IL-1β-induced pressor responses. An SFO lesion minimized the IL-1β-induced expression of inflammatory and RAS components as well as c-Fos, an indicator of neuronal excitation, in the PVN. These studies demonstrate that circulating IL-1β, which increases in cardiovascular disorders such as hypertension and heart failure, acts on the SFO to increase inflammation and RAS activity in the SFO and PVN and that intervening in these neurochemical processes in the SFO can significantly reduce the sympathetic response.
我们之前报道过,将促炎细胞因子白细胞介素-1β(IL-1β)微量注射到穹窿下器(SFO)会引发升压反应,同时伴随着SFO和下丘脑室旁核(PVN)中炎症和肾素-血管紧张素系统(RAS)活性的增加。本研究旨在确定血源性IL-1β是否会在SFO和PVN中诱导类似的神经化学变化,如果是,SFO水平上炎症和RAS活性的增加是否会协调对循环IL-1β的交感兴奋反应。在乌拉坦麻醉的雄性Sprague-Dawley大鼠中,静脉注射IL-1β(500 ng)会升高血压、心率、肾交感神经活性,并增加SFO和PVN中血管紧张素转换酶、血管紧张素II 1a型受体、环氧化酶-2、肿瘤坏死因子-α、IL-1β以及肿瘤坏死因子-α p55受体和IL-1受体的mRNA水平。预先向SFO微量注射血管紧张素II 1a型受体阻滞剂氯沙坦(1 μg)、血管紧张素转换酶抑制剂卡托普利(1 μg)或环氧化酶-2抑制剂NS-398(2 μg)可减弱这些兴奋性介质在SFO及其下游PVN中的表达以及IL-1β诱导的升压反应。SFO损伤可使PVN中IL-1β诱导的炎症和RAS成分以及神经元兴奋指标c-Fos的表达降至最低。这些研究表明,在高血压和心力衰竭等心血管疾病中增加的循环IL-1β作用于SFO,以增加SFO和PVN中的炎症和RAS活性,并且干预SFO中的这些神经化学过程可显著降低交感反应。